The response to TRH, LH-RH, metyrapone and vasopressin in patients with hypothalamo-pituitary disorders.
D000172:Acromegaly / Q000378:metabolism; D000239:Adenoma, Acidophil / Q000378:metabolism; D000238:Adenoma, Chromophobe / Q000378:metabolism; D000328:Adult; D001932:Brain Neoplasms / Q000378:metabolism; D003397:Craniopharyngioma / Q000378:metabolism; D003919:Diabetes Insipidus / Q000378:metabolism; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D008579:Meningioma / Q000378:metabolism; D008797:Metyrapone / Q000494:pharmacology*; D010871:Pinealoma / Q000378:metabolism; D010906:Pituitary Hormone-Releasing Hormones / Q000494:pharmacology*; D010911:Pituitary Neoplasms / Q000378:metabolism*; D011863:Radioimmunoassay; D013972:Thyrotropin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*; D014667:Vasopressins / Q000494:pharmacology*
D010906:Pituitary Hormone-Releasing Hormones; D014667:Vasopressins; D013973:Thyrotropin-Releasing Hormone; D007986:Luteinizing Hormone; D013972:Thyrotropin; D008797:Metyrapone